Sixera Pharma AB
Small biotech developing first treatment for rare Netherton syndrome.
Oversikt
- 1–4
- Ansatte
- ≤1t SEK
- Omsetning
- 2012
- Grunnlagt
Nøkkelbeslutningstakere
Hans Olivecrona
Chief Medical Officer
Margit Mahlapuu
Chief Scientific Officer, Board member
Torbjörn Egelrud
Board member
Maria Klockare
Clinical Program Director
+5 flere kontakter i Funnelfeedr
Beskrivelse
Sixera Pharma is a small biopharmaceutical company established in Stockholm in 2013. The company originated from a project spun out of Swedish Orphan Biovitrum (Sobi) and Arexis. Their core mission is to develop their lead compound, SXR1096, into the first available treatment for Netherton syndrome....
Tagger
Nøkkelord
Teknologier i bruk
Bedriftsinformasjon
- Bransje
- Bioteknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- MVA-nummer
- SE556901476301
Beslutningstakere
9 kontakter i FunnelfeedrHans Olivecrona
Chief Medical Officer
Margit Mahlapuu
Chief Scientific Officer, Board member
Torbjörn Egelrud
Board member
Maria Klockare
Clinical Program Director
Jean Nordström
Founder
William Gunnarsson
Board member
Maarten de Château
Chief Executive Officer, Board member
Thomas Eldered
Board member
Lennart Hansson
Chairman of the Board
Lignende bedrifter
20 lignende bedrifter i Funnelfeedr
OxThera AB
0 ansatteDeveloping novel biotherapies for rare kidney diseases like Primary Hyperoxaluria.
OxThera Intellectual Property AB
0 ansatteDeveloping novel biotherapies for rare kidney diseases like Primary Hyperoxaluria.
AUTHERA AS
5 ansatteDeveloping novel FcRn-targeting biologics for therapeutic applications.
Devyser Diagnostics AB
1–4 ansattePioneering simple, fast, accurate genetic testing solutions for global laboratories.
Devyser AB
50–99 ansattePioneering simple, fast, accurate genetic testing solutions for global laboratories.
Utforsk mer
Spørsmål om Sixera Pharma AB
Vil du se Funnelfeedr i aksjon?
Book en gratis demo og oppdag hvordan Funnelfeedr hjelper deg med å finne og konvertere dine ideelle kunder.
Book en demo